# Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients

> **NCT03197805** · NA · TERMINATED · sponsor: **Centre Jean Perrin** · enrollment: 26 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** PAM 50 test

## Key facts

- **NCT ID:** NCT03197805
- **Lead sponsor:** Centre Jean Perrin
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-16
- **Primary completion:** 2019-05-28
- **Final completion:** 2019-05-28
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Take care recommendations for Her2 equivok patients has changed.
- **Last updated:** 2019-07-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03197805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03197805, "Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03197805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*